Jeffrey Nau, Oyster Point CEO (Oyster Point Pharma)
Small biotech Oyster Point sets up pitch to disrupt dry eye market with nasal spray
Oyster Point Pharma — a small Princeton, NJ-based biotech looking to disrupt a massive eye drug market largely monopolized by two therapies — has
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
